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Sydney Brenner is a man of many
ideas. Asked to rate one of his more
recent ones, which has spawned a
company called Lynx Therapeutics,
Inc., Brenner describes it as ‘‘pretty
good compared to my previous work.’’
But then, he says, ‘‘that is a safe
statement to make, because you
might think that all the previous ideas
were terrible.’’
Or not. After all, this is the man who
co-discovered mRNA and the triplet
theory of translation. Then in the mid-
1960s he selected the worm
Caenorhabditis elegans as the next
model organism, thus giving birth to
an entire ¢eld of study. Now, of¢cially
retired from his more onerous duties,
Brenner constitutes the entire
scienti¢c advisory board of Lynx, and
is masterminding the implementation
of his idea at the company’s Hayward,
CA, headquarters.
‘‘What Lynx does so uniquely,’’
says CEO Norrie Russell, ‘‘is the next
and necessary evolutionary step of
DNA analysis.’’ From the isolation of
single genes, biologists have moved to
automated sequencing and DNA
microarrays containing a few thousand
genes. But still, says Russell, ‘‘there
needed to come the next step, and the
next step is Lynx.’’
Lynx technology essentially
transfers the contents of a genomic or
cDNA library onto beads, with each
bead containing thousands of copies of
one member of the original library.
Using those beads, says Brenner, ‘‘in
one fell swoop we can remove (for
analysis) all the pieces of nucleic acid
that vary in abundance.’’ Millions of
beads can be hybridized, sorted, and
sequenced, allowing the company to
¢sh out sequences that are over- or
under-expressed, and identify single
nucleotidepolymorphisms(SNPs) that
are associated with a disease. And that,
promises Brenner, is just for starters.
Developing a technology
Brenner started thinking about what
is now the Lynx technology in the late
1980s in England. He tried to raise
some venture capital but failed. ‘‘Most
people thought it was too risky,’’ says
Brenner. ‘‘They were pretty much
right.’’
But there was one place, he says,
where that risk could be overcome.
The risk arose because a unique
combination of skills ^ in molecular
biology, chemistry, optics and
computing ^ were needed to produce
the ¢nal product. ‘‘It could only have
been done in the [San Francisco] Bay
Area where you have all these
technologies together,’’ says Brenner.
Sydney Brenner is taking on the
challenge of genomics.
The next problem was the money.
Luckily Brenner knew Sam Eletr,
who was then the CEO of a small
biotech company called Lynx. Lynx
had been spun out of Applied Bio-
systems, Inc. (ABI; Foster City, CA)
to exploit the possible antisense
applications of ABI’s phosphor-
amidate chemistry. But, as Russell
puts it, ‘‘by 1995 it was becoming
apparent that the antisense road is a
long and winding road.’’ Technology
met company, and by 1998, when
Lynx sold off its waning interest in
phosphoramidates, the company was
focused entirely on making the
Brenner technology work.
That process, says Brenner, was
‘‘terribly dif¢cult. The one thing I
learned was that inventing and
implementing technology is much
more dif¢cult than doing science.
During development you can not
change your goals ^ you have to get to
the end.’’
DNA onto beads
A need for a better DNA sequencing
method was what originally inspired
Brenner. ‘‘By the time I retired to
California I had already worked out
the sequencing idea,’’ he says. ‘‘But to
make it work we needed a method for
handling lots of templates. Later we
came to realize that it was this loading
technology that was central, and the
sequencing was just one application.’’
The loading technology, or
Megaclone, uses a system of tags and
anti-tags. The anti-tags are
constructed on 5-Wm microbeads by
mix-and-divide combinatorial
synthesis. The tags are appended to
cDNAs during a cloning step. The
clones are then ampli¢ed to produce
thousands of copies of any one cDNA-
plus-tag combination. When DNA
and beads are mixed, thousands of
copies of a given cDNA plus tag
hybridize to their cognate anti-tagged
bead. A library of millions of cDNAs
has been converted to a library of
beads, each with thousands of copies
of a single cDNA.
Accurate hybridization is crucial if
Megaclone is to have any meaning
whatsoever. ‘‘It really is computing
with molecules,’’ says Brenner. In an
interesting parallel with his earlier
work with mRNA triplets, Brenner
says that to make the hybridization
work ‘‘we had to de¢ne a DNA
language.’’
The language must not allow for
any signi¢cant amount of cross-
hybridization. This led the Lynx team
to create the tags and anti-tags out of
eight four-base ‘‘words.’’ Each step in
tag synthesis involves the addition of
an entire word, so even the closest
relative of a given tag will differ by an
entire word, not a single base. This
reduces cross-hybridization.
Additionally, the melting temperature
of all correct tag^anti-tag
combinations should be identical, as
every word forms the same number of
A:T base pairs (three) and G:C base
pairs (one). The ¢nal safety step was
to exclude guanine nucleotides from
one entire tag strand. This should
eliminate self-annealing driven by
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self-complementarity, and ensure that
no tag contains the type of
palindromic sequence required for
recognition by most restriction
enzymes.
Once the cDNAs are attached to
beads,onecDNAstrandisligatedtothe
tagandtheotherstrandisstrippedaway.
The single-stranded cDNA now acts to
detect added, labeled cDNA by
hybridization. For example, as in a
DNA microarray experiment, cDNA
samples from quiescent and cycling
cells can be labeled blue and red,
respectively, before hybridization.
Fluorescence-activated cell sorting
(FACS)ofthebeadsthenyieldscDNAs
from blue beads (greater expression in
quiescent cells) and red beads (greater
expression in cycling cells).
Staring at beads
DNA from FACS-sorted beads can be
sequenced conventionally, and used
as the raw material for a DNA
microarray uniquely suited to your
problem of interest.
As an alternative to sorting, beads
can be analyzed using Brenner’s
original sequencing idea. In massively
parallel signature sequencing (MPSS)
the beads are simultaneously
decoded. Exhaustive sequencing has
been used for transcript pro¢ling in
the past, notably by Incyte Genomics,
Inc. (Palo Alto, CA). In theory this
could give an exact digital readout of
how many copies of each transcript are
present in a cell. But standard
sequencing technology is too slow and
too costly to effect anything
approaching saturation coverage, so
the end result is vague estimate of
relative abundance based on
sequencing a few thousand cDNAs
sampled from the millions of
transcripts present in a cell.
MPSS aims to ful¢ll the promise of
digital precision by increasing speed
and throughput. The beads from
Megaclone are immobilized in a £ow
cell, and the comings and goings of
£uorescent sequencing probes are
monitored by a CCD camera that is
trained on the microbeads. Hundreds
of thousands of mRNAs can be
identi¢ed in a few days.
And now for the sequencing
The entire cDNA is not sequenced.
Instead, the ingenious sequencing
method identi¢es 16^20 base pair
‘‘signature sequences’’ that can then
be used (if genomic information is
available) to identify the cDNA. If
genomic information is not available
for a clone that is interesting because
of its abundance, the cDNA must be
identi¢ed by conventional
sequencing.
The signature sequence is
identi¢ed four bases at a time. Each
four bases, present as a single-
stranded overhang, is identi¢ed by the
annealing of one of 256 probes. The
probe also contains a binding site for a
type IIs restriction enzyme. Although
the restriction enzyme binds to the
probe, it cleaves within the cDNA,
thus exposing the next four bases for
decoding.
This procedure not only does away
with gels, says Brenner, but ‘‘is
completely parallel. It is the same if
you sequence 1 template or 2 000 000
templates.’’
The competition ^ microarrays
To a casual observer it may sound like
Lynx technology and DNA
microarrays are solving the same
problem. Microarrays have gained a
substantial commercial foothold
thanks to companies like Incyte and
Affymetrix, Inc. (Santa Clara, CA).
But, says Russell, ‘‘I do not think a
standard has already been set. I sense
more and more that investments have
been made (in microarrays) but there
is a growing concern of the limitations
of the microarrays.’’
‘‘The arrays have a lot of
problems,’’ says Brenner. ‘‘If they get
too big you are going to face an issue
that the noise level will increase’’
because of closely related sequences.
But the Lynx technology, he says,
‘‘can be used to explore complete
cDNA libraries in complete depth. I
think this is going to be the tool in
exploring function.’’
Besides, says Brenner, ‘‘we do not
aim to compete with the chips.’’ He
still thinks the best experiment is to
use Megasort followed by analysis of
what he calls, with apologies to the
computing industry, a RISC (reduced
instruction set chip). ‘‘It is going to be
silly to have brain genes on a chip for
liver analysis,’’ he says. ‘‘Our
technology is to de¢ne what ensemble
of stuff you should use.’’
Bring on the super-sequencer
Lynx is generating revenue by
providing genomic discovery services,
and it is gradually increasing its
internal biology efforts. The genomics
focus is drifting into proteomics, with
the development of a liquid-phase 2D
electrophoresis system. Meanwhile
the work on the basic technology
continues, including a Megaclone
scheme that accomplishes a genome-
wide scan for SNPs.
If Lynx is interested primarily in
increasing the applications of
Megaclone, Brenner is clearly still
attached to his original inspiration ^
the new, improved sequencing
method. The short sequence ‘‘runs’’
of MPSS will not bridge repetitive
sequences. But for the increasingly
important task of re-sequencing,
MPSS may be perfect.
‘‘What we have is workable but it is
still the ¢rst stage,’’ he says. ‘‘My
ambition would be to try to sequence
50 bases of 2 000 000 templates and to
do that in 1 day. That is the
production of the entire Venter factory
in one machine.’’
‘‘It isgoingtotakesomeworktogetto
that,’’ he says. ‘‘But I think it is within
reach.’’ If he can complete the journey
from standard sequencing to his
proposedhighpoweredsystemitwillbe
‘‘like going from mainframe transistor
computers all the way to integrated
circuits,’’ he says. ‘‘Perhaps in 5^10
yearstimewecanprovideeveryonewith
a super-sequencer on their desktop.
That would be the hope.’’
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